1242094-27-4

Upstream product

• 1242094-29-6 tert-butyl (S)-2-[5-(4-iodophenyl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylate 
• 1242094-28-5 C₁₈H₂₂INO₅ 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 1242094-26-3 C₁₃H₁₄IN₃ 
• 72-18-4 L-valine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 

Downstream Products

• 1242088-45-4 C₃₈H₄₅N₇O₅ 
• 1228967-79-0 C₃₃H₃₇N₇O₃ 
• 1242088-26-1 C₄₀H₄₇N₇O₇ 
• 1242088-27-2 C₄₁H₅₀N₈O₆ 
• 1242088-67-0 C₄₀H₄₆N₈O₆ 

Relevant academic research and scientific papers

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.